BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Press Releases » Page 41

StemBioSys Launches CELLvo™, Human iPSC-Derived Atrial Cardiomyocytes for Cardiotoxicity Screening

By Leave a Comment

Developed in collaboration with REPROCELL, CELLvo™Â Atrial Cardiomyocyte delivers non-genetically modified human heart cells that are chamber specific and derived from iPS (stem) cells

SAN ANTONIO, June 13, 2023 — StemBioSys, Inc. (StemBioSys) announced the launch of CELLvo™Â Atrial Cardiomyocyte, a “chamber specific” human induced pluripotent stem cell derived cardiomyocyte (hiPSC-CM) designed to function identically to human atrial cardiomyocytes. StemBioSys developed CELLvo™Â Atrial Cardiomyocyte to empower pharmaceutical companies and academics with a more precise, efficient and cost-effective platform for screening new drug products in vitro for cardiotoxicity compared to animal models and other in-vitro methods currently in use. [Read more…]

Saint-Gobain Life Sciences and denovoMATRIX announce investment and expansion of service agreement

By Leave a Comment

DRESDEN, Germany, 20 June, 2023 – denovoMATRIX GmbH, an innovator in cell and gene therapy manufacturing, and Saint-Gobain Life Sciences have expanded their Master Service Agreement with a special focus on products related to the Stem Cell therapy market. At the same time, Saint-Gobain Life Sciences’ investment arm NOVA announces its strategic investment into denovoMATRIX. [Read more…]

Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post Covid Syndrome’

By Leave a Comment

GAINESVILLE, Fla., – Neobiosis, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Today, Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of ‘Post COVID Syndrome (AKA “Long Haul COVID Syndrome”). [Read more…]

StemInov Will Bioproduct the First Cell Therapy Drug to Treat Inflammatory Diseases

By Leave a Comment

NANCY-STRASBOURG, France –StemInov, a biotechnology company developing an innovative biomedicine based on stem cells from umbilical cords to treat inflammatory diseases, septic shock and acute respiratory distress syndrome (ARDS), will bioproduct the first cell therapy drug from umbilical cord stem. In this context, StemInov’s promising disruptive innovations has been selected to join the French Tech – Health20 program launched by the French Government that will accelerate the development of StemInov’s proprietary and collaborative programs with greater visibility in France and internationally. [Read more…]

Gene & cell therapy manufacturing specialist Ascend launches with over $130M of funding as expert teams merge

By Leave a Comment

LONDON, May 9, 2023 — Ascend Gene & Cell Therapies (Ascend), a specialist company innovating manufacturing processes to improve quality, potency, safety and cost enabling better reach for gene therapy technologies, announces that it has launched as a facilitator for gene therapy companies to help translate product ideas into viable clinical programs.

Ascend offers process development, clinical manufacturing, and analytical and regulatory support for biotech companies working in advanced modalities requiring flexible CMC services. Originally founded by Monograph Capital, Ascend has raised a total of $132.5M, most recently completing a Series A fundraise led by Abingworth and Petrichor, supported by DCVC Bio, 4BIO Capital, Cathay Health, Deerfield Management, Digitalis Ventures and Ajinomoto Co., Inc. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0